One person dies every 50 seconds in the U.S. from cancer, and an estimated 39% of people in the country will develop cancer during their lifetime. Survival rates have improved in recent decades from innovations and combinations of treatments, including surgery, chemotherapy, radiation, immunotherapy and biotechnology. Still, some cancers resist treatment or recur.
More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children. Responsible for 75% of all pediatric leukemia diagnoses, ALL is a rapid-onset blood cancer, preventing the body from producing mature, infection-fighting white blood cells, sometimes within a matter of months.
MAPLE GROVE, Minn., Oct. 27, 2026 /PRNewswire/ — Vincora (NeoChord, Inc. d/b/a Vincora), a medical technology company developing transcatheter therapies for mitral valve repair, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) to initiate a U.S. Early Feasibility Study (EFS) of its investigational Transcatheter Chordal Repair System for the treatment of degenerative mitral valve regurgitation.
Researchers at Baylor College of Medicine have discovered a new strategy that glioblastoma, the most common and aggressive form of adult brain cancer, uses to fuel its own growth. Published in the journal Neuron, the study shows in animal models that glioblastoma hijacks the activity of neighboring brain cells, flipping them from a role that limits tumor growth to one that promotes it. The findings point to new treatment possibilities for this deadly cancer, which has seen only minimal gains in patient survival over the past half century.
Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor.
A joint research team led by KAIST has used a small, implantable neural chip to wirelessly monitor real-time changes in a neurotransmitter involved in memory and learning after an Alzheimer’s drug has been administered.
Tibial stress fractures are among the most common overuse injuries affecting military personnel, but they can be difficult to identify in their earliest stages. Small stresses in the bone may develop before an injury becomes apparent through conventional diagnostic tools, creating a window of opportunity for earlier detection to enable intervention.
Scientists at Trinity College Dublin have made a breakthrough in understanding how cancer cells can evade the cell-killing effects of chemotherapy and enter a “zombie-like state,” called premature senescence, that can attract the wound-healing properties of the immune system.
What if we could use a cancer’s own byproduct to make drugs that destroy tumor cells from the inside? That is what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.
In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient’s own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.